Atossa Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2009-01-01
- Employees
- 12
- Market Cap
- $169.7M
- Introduction
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
- Conditions
- Breast NeoplasmsInvasive Breast CancerEstrogen-receptor-positive Breast CancerHER2-negative Breast Cancer
- Interventions
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 214
- Registration Number
- NCT05607004
- Locations
- 🇺🇸
Tranquility Research, Webster, Texas, United States
🇺🇸Bon Secours Cancer Institute, Midlothian, Virginia, United States
🇺🇸Mayo Clinic Arizona, Phoenix, Arizona, United States
Effect of Oral (Z)-Endoxifen in Premenopausal Women With Measurable Breast Density
- First Posted Date
- 2021-10-05
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT05068388
- Locations
- 🇸🇪
Karma Study Centre, Stockholm, Sweden
Topical Endoxifen in Women
- Conditions
- Mammographic Breast Density
- Interventions
- Drug: PlaceboDrug: Topical endoxifen
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT04616430
- Locations
- 🇸🇪
Karolinska Institutet, Stockholm, Sodersjukhuset, Sweden
AT-301 Nasal Spray in Healthy Adults
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2021-01-19
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT04519788
- Locations
- 🇦🇺
CMAX Clinical Research, Adelaide, South Australia, Australia
A Pre-Surgical PK Study of IM and Intraductally Delivered Fulvestrant
- Conditions
- Female Breast CarcinomaFemale Ductal Carcinoma In Situ
- Interventions
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT02540330
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
🇺🇸The Johns Hopkins School of Medicine, Baltimore, Maryland, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Trial of the ForeCYTE Breast Aspirator for Cytological Testing of Nipple Aspirate Fluid in Women 30-55 Years Old
- Conditions
- Breast Cancer, Preneoplastic Conditions, BRCA
- Interventions
- Device: ForeCYTE Breast Aspirator
- First Posted Date
- 2015-09-03
- Last Posted Date
- 2016-01-25
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Registration Number
- NCT02539615
- Locations
- 🇮🇱
Ziv Medical Center, Zefat, Upper Galilee, Israel
🇮🇱The BARUCH PADEH Medical Center, Poriya, Lower Galilee, Israel
ForeCYTE Breast Aspirator for Sample Collection and Cytological Testing of Nipple Aspirate Fluid
- Conditions
- Breast Neoplasms
- Interventions
- Device: ForeCYTE Breast Aspirator
- First Posted Date
- 2014-08-18
- Last Posted Date
- 2016-10-19
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 52
- Registration Number
- NCT02218385
- Locations
- 🇺🇸
Elite Women's Health, New Hyde Park, New York, United States
The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage
- Conditions
- Preneoplastic ConditionsDuctal Carcinoma in SituBreast Cancer
- Interventions
- Device: Nipple aspiratorDevice: Ductal lavage microcatheterDevice: Blood draw
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2023-07-20
- Lead Sponsor
- Atossa Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT02121873
- Locations
- 🇺🇸
Dr. Susan Love Research Foundation, Santa Monica, California, United States